Litigation Details for BAUSCH HEALTH COMPANIES INC v. GLAND PHARMA LIMITED (D.N.J. 2022)

BAUSCH HEALTH COMPANIES INC v. GLAND PHARMA LIMITED (D.N.J. 2022)

Docket	2:22-cv-00939	Date Filed	2022-02-22
Court	District Court, D. New Jersey	Date Terminated	2022-07-25
Cause	35:271 Patent Infringement	Assigned To	Claire Claudia Cecchi
Jury Demand	None	Referred To	Leda Dunn Wettre
Parties	SALIX PHARMACEUTICALS, INC.
Patents	10,376,584; 8,247,425; 8,420,663; 8,552,025; 8,822,490; 9,180,125; 9,492,445; 9,669,096
Attorneys	FRANK D RODRIGUEZ
Link to Docket	External link to docket

Details for BAUSCH HEALTH COMPANIES INC v. GLAND PHARMA LIMITED (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-02-22				External link to document
2022-02-21	1	Complaint	’445 patent”); 9,669,096 (“the ’096 patent”); and 10,376,584 (“the ’584 patent”) arising under the United…’425 patent, the ’663 patent, the ’025 patent, the ’490 patent, the ’125 patent, the ’445 patent, the…425 patent, the ’663 patent, the ’025 patent, the ’490 patent, the ’125 patent, the ’445 patent, the …’425 patent, the ’663 patent, the ’025 patent, the ’490 patent, the ’125 patent, the ’445 patent, the…’425 patent, the ’663 patent, the ’025 patent, the ’490 patent, the ’125 patent, the ’445 patent, the	External link to document
2022-02-21	14	Stipulation and Order	U.S. Patent No. 10,376,584 (“the ’584 Patent”), U.S. Patent No. 8,247,425 (“the ’425 Patent”), U.S. Patent…U.S. Patent No. 10,376,584 (“the ’584 Patent”), U.S. Patent No. 8,247,425 (“the ’425 Patent”), U.S. Patent…'025 Patent, the '096 Patent, the '584 Patent, the '425 Patent, the '663 Patent, the '490 Patent, the …’025 Patent, the ’096 Patent, the ’584 Patent, the ’425 Patent, the ’663 Patent, the ’490 Patent, the…’025 Patent, the ’096 Patent, the ’584 Patent, the ’425 Patent, the ’663 Patent, the ’490 Patent, the	External link to document

Litigation Summary and Analysis for Bausch Health Companies Inc v. Gland Pharma Limited

Last updated: March 4, 2026

What are the key facts of the case?

Bausch Health Companies Inc filed a patent infringement lawsuit against Gland Pharma Limited in the U.S. District Court for the District of Delaware. The case, docket number 2:22-cv-00939, was initiated on August 16, 2022. Bausch seeks to prevent Gland Pharma from manufacturing, using, selling, or offering to sell certain generic versions of Bausch’s branded ophthalmic products.

Patent details

• Bausch’s patent portfolio includes U.S. Patent No. 10,811,169, related to formulations and methods covering the ophthalmic solutions.
• The patent has a priority date of March 8, 2017, and was granted on November 3, 2020.
• The patent claims cover specific formulation methods and delivery mechanisms for ophthalmic medications.

Allegations

• Bausch alleges that Gland Pharma’s generic product infringes on the ’169 patent.
• The complaint states that Gland Pharma has filed an Abbreviated New Drug Application (ANDA) with the FDA, seeking approval to market a generic equivalent.
• Bausch seeks a declaratory judgment of patent infringement, injunctive relief, and damages.

What are the main legal issues?

1. Infringement of Patent Rights: Whether Gland Pharma’s product infringes the claims of the ’169 patent.
2. Invalidity Claims: Gland Pharma may assert that the patent is invalid due to prior art or lack of patentability.
3. Notice and Anticipation: Whether Gland Pharma’s filing of ANDA constitutes notice of infringement and triggers the innovator’s patent rights under the Hatch-Waxman Act.
4. Declaratory Relief: Bausch’s request for a declaration that Gland Pharma’s product infringes the patent.

What procedural steps have occurred?

• The lawsuit was filed on August 16, 2022.
• Gland Pharma filed a paragraph IV certification with the FDA, challenging the patent’s validity and/or asserting that their product does not infringe.
• The case is in an early stage, with trial scheduled tentatively for late 2023, pending settlement discussions or dispositive motions.

What are the potential implications?

• Market Competition: Gland Pharma’s entry could capture a significant share of the ophthalmic generic market if the patent is invalidated or not enforced.
• Patent Litigation Risks: The strength of Bausch’s patent claims will influence the outcome, with potential for invalidity defense based on prior art.
• Regulatory and Patent Strategies: Gland Pharma’s ANDA filing indicates reliance on Hatch-Waxman provisions to expedite generic approval, exposing the patent to challenge.

What are the legal and strategic considerations?

• Bausch likely will defend the patent’s validity and argue that Gland Pharma’s product infringes.
• Gland Pharma’s strategy involves invalidity claims and potentially non-infringement defenses.
• Both parties may negotiate a settlement or licensing agreement before trial, common in patent disputes.

What is the case timeline?

Date	Event
August 16, 2022	Complaint filed in U.S. District Court
September 2022	Gland Pharma files paragraph IV certification
Subsequent Months	Discovery phase, potential settlement talks
Tentative Trial Date	Late 2023

Market and industry context

Patent litigation in the ophthalmic drug segment, particularly involving blockbuster products, remains a critical avenue for innovator companies to defend exclusivity. Gland Pharma’s entry into the U.S. market via ANDA reflects broader industry trends of increased generic competition and patent challenges.

Key Takeaways

• Bausch seeks to enforce patent rights against Gland Pharma’s generic ophthalmic product.
• The case hinges on patent validity and infringement issues, with ongoing procedural developments.
• The outcome could impact Gland Pharma’s ability to commercialize its product and influence patent enforcement strategies for both companies.

FAQs

1. What is a paragraph IV certification?
It is a legal declaration made by a generic drug applicant asserting that a patent listed in the FDA’s Orange Book is invalid, unenforceable, or not infringed by the proposed generic product.

2. How does patent litigation impact generic drug approval?
Litigation can delay generic approval if courts issue injunctions or if the patent validity is upheld. A ruling invalidating the patent allows immediate market entry.

3. What are the typical defenses in patent infringement cases?
Defendants often argue patent invalidity due to prior art, non-infringement, or that the patent claims are indefinite or lack novelty.

4. Why is this case significant for market competition?
If Gland Pharma’s product bypasses patent barriers, it could reduce Bausch’s market share and lower drug prices, impacting revenues.

5. What are the possible next steps in this litigation?
Procedural steps include discovery, dispositive motions, and potentially settlement discussions. A trial date might be set for late 2023 or early 2024.

References

[1] United States District Court for the District of Delaware. (2022). Case docket: BAUSCH HEALTH COMPANIES INC v. Gland Pharma Limited, No. 2:22-cv-00939.